Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RegMed Daily, Mid-Day, 10/19/11, my newest relief, EU markets close at 11:30am, EST each day

The 6 W’s: Who, what, where, when, why and what of it …


High stock market volatility … will persist until the RegMed universe offers … news; stimulating … attractive near and long-term returns.


This is not … currently … a feel good environment … but, quarterly earnings are coming (even though – LPS <loss per share> might NOT be good – however, quarterly milstone attainment is happening - albiet quietly and advancement of development … should highlight … future appreciation. Also, cash positions remain what they are … but, most runways are … enough through 2012 … when markets return or better, partners emerge!!


Notice … trials are still … being announced while others are continuing or being recruited … again quietly …  new team members are being recruited … I have seen … NO … failures announced (so, risk profiles remain the same or  positive)!


I have also … not seen so many lows … with less EU “tear gas” and debt politics … transition is upon us. Faith is NOT a measureable factor but … I percieve BETTER days … for our universe and portfolios!!


Mid-Day: The NASDAQ is DOWN -17.20 (-0.65%) to 2,640.23. The Dow is UP +24.37 (+0.21%) to 11,601.42.

Mid-Day Movers: BioMimetic (NASDAQ:BMTI), BioTime (AMex: BTX), Dendreon (NASDAQ:DNDN), Geron (NASDAQ:GERN), International Stem Cell (OTC BB: ISCO), Neuralstem (AMEX: CUR), Opexa (OPXA), Pluristem (NASDAQ:PSTI), ReNeuron (RENE.LON) and Tengion (TNGN)


What’s new in the regenerative medicine/stem cell market …

NeoStem’s (AMEX: NBS) Progenitor Cell Therapy (PCT) adds to Management to meet Demand: Industry veterans join PCT to assist client-focused development, manufacturing and growing portfolio of cellular therapeutic candidates. The bottom Line: Dr. Fong and Dr. O’Neill lend their expertise to PCT’s clients and to NBS’ preclinical and clinical development programs. These additions enable their expanding client base.

Abbott Laboratories announced plans this morning to split itself in 2, spinning off its $18B pharmaceuticals arm under a new name. The bottom line, that should signal trouble to investors in other drug companies like Pfizer, Merck, and Bristol-Myers Squibb, because it signals that pharmaceuticals is becoming a lot less appealing as a business. Investors cheered the plan, bidding shares up 5% to $55, close to the stock’s 52-week high.